Skip to main content
Top

07-07-2015 | Gout | Review | Article

Global epidemiology of gout: prevalence, incidence and risk factors

Journal: Nature Reviews Rheumatology

Authors: Chang-Fu Kuo, Matthew J. Grainge, Weiya Zhang, Michael Doherty

Authors: Chang-Fu Kuo, Matthew J. Grainge, Weiya Zhang, Michael Doherty

Publisher: Nature Publishing Group UK

Abstract

Gout is a crystal-deposition disease that results from chronic elevation of uric acid levels above the saturation point for monosodium urate (MSU) crystal formation. Initial presentation is mainly severely painful episodes of peripheral joint synovitis (acute self-limiting 'attacks') but joint damage and deformity, chronic usage-related pain and subcutaneous tophus deposition can eventually develop. The global burden of gout is substantial and seems to be increasing in many parts of the world over the past 50 years. However, methodological differences impair the comparison of gout epidemiology between countries. In this comprehensive Review, data from epidemiological studies from diverse regions of the world are synthesized to depict the geographic variation in gout prevalence and incidence. Key advances in the understanding of factors associated with increased risk of gout are also summarized. The collected data indicate that the distribution of gout is uneven across the globe, with prevalence being highest in Pacific countries. Developed countries tend to have a higher burden of gout than developing countries, and seem to have increasing prevalence and incidence of the disease. Some ethnic groups are particularly susceptible to gout, supporting the importance of genetic predisposition. Socioeconomic and dietary factors, as well as comorbidities and medications that can influence uric acid levels and/or facilitate MSU crystal formation, are also important in determining the risk of developing clinically evident gout.

Nat Rev Rheumatol 2015;11:649–662. doi:10.1038/nrrheum.2015.91

Literature
1.
Kuo, C. F., Grainge, M. J., Mallen, C., Zhang, W. & Doherty, M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann. Rheum. Dis. http://​dx.​doi.​org/​10.​1136/​annrheumdis-2014-206410.
2.
Puig, J. G. & Martinez, M. A. Hyperuricemia, gout and the metabolic syndrome. Curr. Opin. Rheumatol. 20, 187–191 (2008).PubMed
3.
Abbott, R. D., Brand, F. N., Kannel, W. B. & Castelli, W. P. Gout and coronary heart disease: the Framingham Study. J. Clin. Epidemiol. 41, 237–242 (1988).PubMed
4.
De Vera, M. A., Rahman, M. M., Bhole, V., Kopec, J. A. & Choi, H. K. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann. Rheum. Dis. 69, 1162–1164 (2010).PubMed
5.
Krishnan, E., Baker, J. F., Furst, D. E. & Schumacher, H. R. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 54, 2688–2696 (2006).PubMed
6.
Kuo, C. F. et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 52, 111–117 (2013).
7.
Yu, K. H. et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res. Ther. 14, R83 (2012).PubMedPubMedCentral
8.
So, A. Epidemiology: Gout—bad for the heart as well as the joint. Nat. Rev. Rheumatol. 6, 386–387 (2010).PubMed
9.
Community Oriented Program for Control of Rheumatic Diseases (COPCORD). COPCORD Website[online], (2015).
10.
Roddy, E., Zhang, W. & Doherty, M. The changing epidemiology of gout. Nat. Clin. Pract. Rheumatol. 3, 443–449 (2007).PubMed
11.
Doherty, M. et al. Gout: why is this curable disease so seldom cured? Ann. Rheum. Dis. 71, 1765–1770 (2012).PubMed
12.
Chang, S. J. et al. High prevalence of gout and related risk factors in Taiwan's Aborigines. J. Rheumatol. 24, 1364–1369 (1997).PubMed
13.
Chou, C. T. & Lai, J. S. The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br. J. Rheumatol. 37, 258–262 (1998).PubMed
14.
Tu, F. Y. et al. Prevalence of gout with comorbidity aggregations in southern Taiwan. Joint Bone Spine 82, 45–51 (2015).PubMed
15.
Rose, B. S. & Prior, I. A. A surgery of rheumatism in a rural New Zealand Maori community. Ann. Rheum. Dis. 22, 410–415 (1963).PubMedPubMedCentral
16.
Brauer, G. W. & Prior, I. A. A prospective study of gout in New Zealand Maoris. Ann. Rheum. Dis. 37, 466–472 (1978).PubMedPubMedCentral
17.
Klemp, P., Stansfield, S. A., Castle, B. & Robertson, M. C. Gout is on the increase in New Zealand. Ann. Rheum. Dis. 56, 22–26 (1997).PubMedPubMedCentral
18.
Pascart, T., Oehler, E. & Flipo, R. M. Gout in French Polynesia: a survey of common practices. Joint Bone Spine 81, 374–375 (2014).PubMed
19.
Khaltaev, N. & Benevolenskaya, L. I. in The Primary Prevention of Rheumatic Diseases (Ed. Wigley, R. D.) 11–20 (Parthenon Publishing Group, 1994).
20.
Obregon-Ponce, A., Iraheta, I., Garcia-Ferrer, H., Mejia, B. & Garcia-Kutzbach, A. Prevalence of musculoskeletal diseases in Guatemala, Central America: the COPCORD study of 2 populations. J. Clin. Rheumatol. 18, 170–174 (2012).PubMed
21.
Davatchi, F. et al. WHO–ILAR COPCORD Study (stage 1, urban study) in Iran. J. Rheumatol. 35, 1384 (2008).PubMed
22.
Sandoughi, M. et al. Prevalence of musculoskeletal disorders in southeastern Iran: a WHO–ILAR COPCORD study (stage 1, urban study). Int. J. Rheum. Dis. 16, 509–517 (2013).PubMed
23.
Forghanizadeh, J. et al. Prevalence of rheumatic disease in Fasham. Razi Journal of Medical Sciences 3, 182–191 (1995).
24.
Moghimi, N. et al. WHO–ILAR COPCORD study (stage 1, urban study) in Sanandaj, Iran. Clin. Rheumatol. 34, 535–543 (2013).PubMed
25.
Davatchi, F. et al. Effect of ethnic origin (Caucasians versus Turks) on the prevalence of rheumatic diseases: a WHO–ILAR COPCORD urban study in Iran. Clin. Rheumatol. 28, 1275–1282 (2009).PubMed
26.
Veerapen, K., Wigley, R. D. & Valkenburg, H. Musculoskeletal pain in Malaysia: a COPCORD survey. J. Rheumatol. 34, 207–213 (2007).PubMed
27.
Dans, L. F., Tankeh-Torres, S., Amante, C. M. & Penserga, E. G. The prevalence of rheumatic diseases in a Filipino urban population: a WHO–ILAR COPCORD Study. World Health Organization. International League of Associations for Rheumatology. Community Oriented Programme for the Control of the Rheumatic Diseases. J. Rheumatol. 24, 1814–1819 (1997).PubMed
28.
Al-Arfaj, A. S. Hyperuricemia in Saudi Arabia. Rheumatol. Int. 20, 61–64 (2001).PubMed
29.
Cakir, N. et al. The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol. Int. 32, 895–908 (2012).PubMed
30.
Muller, A. S. Population Studies on the Prevalence of Rheumatic Diseases in Liberia and Nigeria. Thesis, University of Leiden (1970).
31.
Beighton, P., Soskolne, C. L., Solomon, L. & Sweet, B. Serum uric-acid levels in a Nama (Hottentot) community in South-West-Africa. S. Afr. J. Sci. 70, 281–283 (1974).
32.
Beighton, P., Daynes, G. & Soskolne, C. L. Serum uric acid concentrations in a Xhosa community in the Transkei of Southern Africa. Ann. Rheum. Dis. 35, 77–80 (1976).PubMedPubMedCentral
33.
Lutalo, S. K. Chronic inflammatory rheumatic diseases in black Zimbabweans. Ann. Rheum. Dis. 44, 121–125 (1985).PubMedPubMedCentral
34.
Beighton, P., Solomon, L., Soskolne, C. L. & Sweet, M. B. Rheumatic disorders in the South African Negro. Part IV. Gout and hyperuricaemia. S. Afr. Med. J. 51, 969–972 (1977).PubMed
35.
Wijnands, J. M. et al. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur. J. Epidemiol. (2014).
36.
Zhu, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008 Arthritis Rheum. 63, 3136–3141 (2011).PubMed
37.
Badley E. D. M. Arthritis in Canada: an ongoing challenge (Health Canada, Ottawa, 2003).
38.
Anagnostopoulos, I. et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet. Disord. 11, 98 (2010).PubMedPubMedCentral
39.
Kuo, C. F., Grainge, M. J., Mallen, C., Zhang, W. & Doherty, M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann. Rheum. Dis. http://​dx.​doi.​org/​10.​1136/​annrheumdis-2013-204463.
40.
Sicras-Mainar, A., Navarro-Artieda, R. & Ibanez-Nolla, J. Resource use and economic impact of patients with gout: a multicenter, population-wide study [article in English, Spanish]. Reumatol. Clin. 9, 94–100 (2013).PubMed
41.
Picavet, H. S. & Hazes, J. M. Prevalence of self reported musculoskeletal diseases is high. Ann. Rheum. Dis. 62, 644–650 (2003).PubMedPubMedCentral
42.
Annemans, L. et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005 Ann. Rheum. Dis. 67, 960–966 (2008).PubMed
43.
Bardin, T. et al. Prevalence of gout in the adult population of France in 2013 [abstract]. Ann. Rheum. Dis. 73 (Suppl. 2), 787–788 (2014).
44.
Trifiro, G. et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann. Rheum. Dis. 72, 694–700 (2013).PubMed
45.
Reis, C. & Viana Queiroz, M. Prevalence of self-reported rheumatic diseases in a Portuguese population. Acta Reumatol. Port. 39, 54–59 (2014).PubMed
46.
Hanova, P., Pavelka, K., Dostal, C., Holcatova, I. & Pikhart, H. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002–2003. Clin. Exp. Rheumatol. 24, 499–507 (2006).PubMed
47.
Minaur, N., Sawyers, S., Parker, J. & Darmawan, J. Rheumatic disease in an Australian Aboriginal community in North Queensland, Australia. A WHO–ILAR COPCORD survey. J. Rheumatol. 31, 965–972 (2004).PubMed
48.
Australian Bureau of Statistics. National Health Survey, summary of results, Australia, 1995 (Australian Bureau of Statistics, Canberra, 1996).
49.
Winnard, D. et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford) 51, 901–909 (2012).
50.
Kawasaki T. S. K. Epidemiology survey of gout using residents' health checks. Gou t and Nucleic Acid Metabolism 30, 66 (2006).
51.
Lee, C. H. & Sung, N. Y. The prevalence and features of Korean gout patients using the National Health Insurance Corporation Database. J. Korean Rheum. Assoc. 18, 94–100 (2011).
52.
Census and Statistics Department. Special Topics Report No. 27 on Social Statistics: persons with disabilities and chronic diseases (Government of Hong Kong Special Adminstrative Region, 2001).
53.
Teng, G. G. et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann. Rheum. Dis. 71, 924–928 (2012).PubMed
54.
Kuo, C. F. et al. Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan. Ann. Rheum. Dis. 74, 369–374 (2015).PubMed
55.
Isomäki, H. A. & Takkunen, H. Gout and hyperuricemia in a Finnish rural population. Acta Rheumatol. Scand. 15, 112–120 (1969).PubMed
56.
Popert, A. J. & Hewitt, J. V. Gout and hyperuricaemia in rural and urban populations. Ann. Rheum. Dis. 21, 154–163 (1962).PubMedPubMedCentral
57.
Mikuls, T. R. et al. Gout epidemiology: results from the UK General Practice Research Database, 1990–1999 Ann. Rheum. Dis. 64, 267–72 (2005).PubMedPubMedCentral
58.
Robinson, P. C., Taylor, W. J. & Merriman, T. R. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern. Med. J. 42, 997–1007 (2012).PubMed
59.
Chou, C. T. et al. Prevalence of rheumatic diseases in Taiwan: a population study of urban, suburban, rural differences. J. Rheumatol. 21, 302–306 (1994).PubMed
60.
Lin, K. C., Lin, H. Y. & Chou, P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J. Rheumatol. 27, 1045–1050 (2000).PubMed
61.
Chang, H. Y., Pan, W. H., Yeh, W. T. & Tsai, K. S. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993–1996). J. Rheumatol. 28, 1640–1646 (2001).PubMed
62.
Chuang, S. Y., Lee, S. C., Hsieh, Y. T. & Pan, W. H. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993–1996 to 2005–2008 Asia Pac. J. Clin. Nutr. 20, 301–8 (2011).PubMed
63.
Kuo, C. F. et al. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res. Ther. 17, 13 (2015).PubMedPubMedCentral
64.
Pfleger, B. Burden and control of musculoskeletal conditions in developing countries: a joint WHO/ILAR/BJD meeting report. Clin. Rheumatol. 26, 1217–1227 (2007).PubMed
65.
Cardiel, M. H. & Rojas-Serrano, J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin. Exp. Rheumatol. 20, 617–624 (2002).PubMed
66.
Pelaez-Ballestas, I. et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J. Rheumatol. Suppl. 86, 3–8 (2011).PubMed
67.
Reyes-Llerena, G. A. et al. Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study. J. Clin. Rheumatol. 15, 51–55 (2009).PubMed
68.
Granados, Y. et al. Prevalence of musculoskeletal disorders and rheumatic diseases in an urban community in Monagas State, Venezuela: a COPCORD study. Clin. Rheumatol. (2014).
69.
Bremner, J. M. & Lawrence, J. S. Population studies of serum uric acid. Proc. R. Soc. Med. 59, 319–325 (1966).PubMedPubMedCentral
70.
Darmawan, J., Valkenburg, H. A., Muirden, K. D. & Wigley, R. D. The epidemiology of gout and hyperuricemia in a rural population of Java. J. Rheumatol. 19, 1595–1599 (1992).PubMed
71.
Haq, S. A. et al. Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. J. Rheumatol. 32, 348–353 (2005).PubMed
72.
Dai, S. M. et al. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J. Rheumatol. 30, 2245–2251 (2003).PubMed
73.
Chen, S., Du, H., Wang, Y. & Xu, L. The epidemiology study of hyperuricemia and gout in a community population of Huangpu District in Shanghai. Chin. Med. J. (Engl.) 111, 228–230 (1998).
74.
Chopra, A. et al. Prevalence of rheumatic diseases in a rural population in western India: a WHO–ILAR COPCORD Study. J. Assoc. Physicians India 49, 240–246 (2001).PubMed
75.
Farooqi, A. & Gibson, T. Prevalence of the major rheumatic disorders in the adult population of north Pakistan. Br. J. Rheumatol. 37, 491–495 (1998).PubMed
76.
Chaiamnuay, P., Darmawan, J., Muirden, K. D. & Assawatanabodee, P. Epidemiology of rheumatic disease in rural Thailand: a WHO–ILAR COPCORD study. Community Oriented Programme for the Control of Rheumatic Disease. J. Rheumatol. 25, 1382–1387 (1998).PubMed
77.
Minh Hoa, T. T. et al. Prevalence of the rheumatic diseases in urban Vietnam: a WHO–ILAR COPCORD study. J. Rheumatol. 30, 2252–2256 (2003).PubMed
78.
Miao, Z. et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J. Rheumatol. 35, 1859–1864 (2008).PubMed
79.
Nan, H. et al. The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J. Rheumatol. 33, 1346–1350 (2006).PubMed
80.
Zeng, Q. et al. Primary gout in Shantou: a clinical and epidemiological study. Chin. Med. J. (Engl.) 116, 66–69 (2003).
81.
Li, R. et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford) 51, 721–729 (2012).
82.
Mahajan, A., Jasrotia, D. S., Manhas, A. S. & Jamwal, S. S. Prevalence of major rheumatic disorders in Jammu. J. Med. Educ. Res. (2003).
83.
Tsitlanadze, V. G., Kartvelishvili, E., Shakulashvili, N. A. & Shalamberidze, L. P. Incidence and various risk factors for gout in the Georgian SSR [article in Russian]. Ter. Arkh. 59, 18–20 (1987).PubMed
84.
Sagna, Y. et al. Prevalence and associated risk factors of diabetes and impaired fasting glucose in urban population; a study from Burkina Faso. J. Diabetol. 2, 4 (2014).
85.
Mijiyawa, M. & Oniankitan, O. Risk factors for gout in Togolese patients. Joint Bone Spine 67, 441–445 (2000).PubMed
86.
Burch, T. A., O'Brien, W. M., Need, R. & Kurland, L. T. Hyperuricaemia and gout in the Mariana Islands. Ann. Rheum. Dis. 25, 114–116 (1966).PubMedPubMedCentral
87.
Bennett, P. H. & Wood, P. H. N. Population studies of the rheumatic diseases: proceedings of the third international symposium, New York, June 5th–10th, 1966 (Excerpta Medica Foundation, 1968).
88.
Prior, I. A., Rose, B. S., Harvey, H. P. & Davidson, F. Hyperuricaemia, gout, and diabetic abnormality in Polynesian people. Lancet 1, 333–338 (1966).PubMed
89.
Zimmet, P. Z., Whitehouse, S., Jackson, L. & Thoma, K. High prevalence of hyperuricaemia and gout in an urbanised Micronesian population. Br. Med. J. 1, 1237–1239 (1978).PubMedPubMedCentral
90.
Jackson, L. et al. Hyperuricaemia and gout in Western Samoans. J. Chronic Dis. 34, 65–75 (1981).PubMed
91.
O'Sullivan, J. B. Gout in a New England town: a prevalence study in Sudbury, Massachusetts. Ann. Rheum. Dis. 31, 166–169 (1972).PubMedPubMedCentral
92.
Maynard, J. W. et al. Racial differences in gout incidence in a population-based cohort: Atherosclerosis Risk in Communities Study. Am. J. Epidemiol. 179, 576–583 (2014).PubMed
93.
Arromdee, E., Michet, C. J., Crowson, C. S., O'Fallon, W. M. & Gabriel, S. E. Epidemiology of gout: is the incidence rising? J. Rheumatol. 29, 2403–2406 (2002).PubMed
94.
Stewart, O. J. & Silman, A. J. Review of UK data on the rheumatic diseases--4. Gout. Br. J. Rheumatol. 29, 485–488 (1990).PubMed
95.
Elliot, A. J., Cross, K. W. & Fleming, D. M. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994–2007 Ann. Rheum. Dis. 68, 1728–1733 (2009).PubMed
96.
Hall, A. P., Barry, P. E., Dawber, T. R. & McNamara, P. M. Epidemiology of gout and hyperuricemia. A long-term population study. Am. J. Med. 42, 27–37 (1967).PubMed
97.
Kippen, I., Klinenberg, J. R., Weinberger, A. & Wilcox, W. R. Factors affecting urate solubility in vitro. Ann. Rheum. Dis. 33, 313–317 (1974).PubMedPubMedCentral
98.
Lin, K. C., Lin, H. Y. & Chou, P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J. Rheumatol. 27, 1501–1505 (2000).PubMed
99.
Duskin-Bitan, H. et al. The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort. Clin. Rheumatol. 33, 549–553 (2014).PubMed
100.
Zalokar, J., Lellouch, J., Claude, J. R. & Kuntz, D. Serum uric acid in 23,923 men and gout in a subsample of 4,257 men in France. J Chronic Dis. 25, 305–312 (1972).PubMed
101.
Campion, E. W., Glynn, R. J. & DeLabry, L. O. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am. J. Med. 82, 421–426 (1987).PubMed
102.
Mituszova, M., Judak, A., Poor, G., Gyodi, E. & Stenszky, V. Clinical and family studies in Hungarian patients with gout. Rheumatol. Int. 12, 165–168 (1992).PubMed
103.
Blumberg, B. S. Heredity of gout and hyperuricemia. Arthritis Rheum. 8, 627–647 (1965).PubMed
104.
Emmerson, B. T. Heredity in primary gout. Australas. Ann. Med. 9, 168–175 (1960).PubMed
105.
Hauge, M. & Harvald, B. Heredity in gout and hyperuricemia. Acta Med. Scand. 152, 247–257 (1955).PubMed
106.
Smyth, C. J., Cotterman, C. W. & Freyberg, R. H. The genetics of gout and hyperuricaemia. Ann. Rheum. Dis. 7, 248 (1948).PubMed
107.
Grahame, R. & Scott, J. T. Clinical survey of 354 patients with gout. Ann. Rheum. Dis. 29, 461–468 (1970).PubMedPubMedCentral
108.
Copeman, W. S. C. A short history of the gout and the rheumatic diseases (University of California Press, 1964).
109.
Smyth, C. J., Cotterman, C. W. & Freyberg, R. H. The genetics of gout and hyperuricaemia; an analysis of 19 families. J. Clin. Invest. 27, 749–759 (1948).PubMedPubMedCentral
110.
Cobb, S. The frequency of the rheumatic diseases (Harvard University Press, 1971).
111.
Prior, I. A., Welby, T. J., Ostbye, T., Salmond, C. E. & Stokes, Y. M. Migration and gout: the Tokelau Island migrant study. Br. Med. J. (Clin. Res. Ed.) 295, 457–461 (1987).
112.
Choi, H. K., Zhu, Y. & Mount, D. B. Genetics of gout. Curr. Opin. Rheumatol. 22, 144–151 (2010).PubMed
113.
Turner, J. J. et al. UROMODULIN mutations cause familial juvenile hyperuricemic nephropathy. J. Clin. Endocrinol. Metab. 88, 1398–1401 (2003).PubMed
114.
Kottgen, A. et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat. Genet. 45, 145–154 (2013).PubMed
115.
Phipps-Green, A. J. et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann. Rheum. Dis. http://​dx.​doi.​org/​10.​1136/​annrheumdis-2014-205877.
116.
Rice, T. et al. Heterogeneity in the familial aggregation of fasting serum uric acid level in five North American populations: the Lipid Research Clinics Family Study. Am. J. Med. Genet. 36, 219–225 (1990).PubMed
117.
Nath, S. D. et al. Genome scan for determinants of serum uric acid variability. J. Am. Soc. Nephrol. 18, 3156–3163 (2007).PubMed
118.
Wilk, J. B. et al. Segregation analysis of serum uric acid in the NHLBI Family Heart Study. Hum. Genet. 106, 355–359 (2000).PubMed
119.
Hak, A. E., Curhan, G. C., Grodstein, F. & Choi, H. K. Menopause, postmenopausal hormone use and risk of incident gout. Ann. Rheum. Dis. 69, 1305–1309 (2010).PubMed
120.
Royal College of General Practitioners, Office of Population Censuses and Surveys & Department of Health and Social Security. Morbidity statistics from general practice 1970–1971: socio-economic analyses (H. M. S. O., 1982).
121.
Zollner, N. & Griebsch, A. Diet and gout. Adv. Exp. Med. Biol. 41, 435–442 (1974).PubMed
122.
Gordon, T. & Kannel, W. B. Drinking and its relation to smoking, BP, blood lipids, and uric acid. The Framingham study. Arch. Intern. Med. 143, 1366–1374 (1983).PubMed
123.
Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W. & Curhan, G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N. Engl. J. Med. 350, 1093–1103 (2004).PubMed
124.
Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W. & Curhan, G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363, 1277–1281 (2004).PubMed
125.
Choi, H. K. & Curhan, G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336, 309–312 (2008).PubMedPubMedCentral
126.
Perheentupa, J. & Raivio, K. Fructose-induced hyperuricaemia. Lancet 2, 528–531 (1967).PubMed
127.
Batt, C. et al. Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout. Ann. Rheum. Dis. 73, 2101–2106 (2014).PubMed
128.
Choi, H. K., Willett, W. & Curhan, G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum. 56, 2049–2055 (2007).PubMed
129.
Zhang, Y. et al. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum. 64, 4004–4011 (2012).PubMedPubMedCentral
130.
Choi, H. K., Gao, X. & Curhan, G. Vitamin C intake and the risk of gout in men: a prospective study. Arch. Intern. Med. 169, 502–507 (2009).PubMedPubMedCentral
131.
Maynard, J. W. et al. Incident gout in women and association with obesity in the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Med. 125, 717.e9–717.e17 (2012).
132.
McAdams-DeMarco, M. A., Maynard, J. W., Baer, A. N. & Coresh, J. Hypertension and the risk of incident gout in a population-based study: the atherosclerosis risk in communities cohort. J. Clin. Hypertens. (Greenwich) 14, 675–679 (2012).
133.
Rho, Y. H. et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J. Korean Med. Sci. 20, 1029–1033 (2005).PubMedPubMedCentral
134.
Cea Soriano, L., Rothenbacher, D., Choi, H. K. & Garcia Rodriguez, L. A. Contemporary epidemiology of gout in the UK general population. Arthritis Res. Ther. 13, R39 (2011).PubMedPubMedCentral
135.
Domrongkitchaiporn, S. et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J. Am. Soc. Nephrol. 16, 791–799 (2005).PubMed
136.
Obermayr, R. P. et al. Predictors of new-onset decline in kidney function in a general middle-European population. Nephrol. Dial. Transplant. 23, 1265–1273 (2008).PubMed
137.
Obermayr, R. P. et al. Elevated uric acid increases the risk for kidney disease. J. Am. Soc. Nephrol. 19, 2407–2413 (2008).PubMedPubMedCentral
138.
Krishnan, E. Chronic kidney disease and the risk of incident gout among middle-aged men: a seven-year prospective observational study. Arthritis Rheum. 65, 3271–3278 (2013).PubMed
139.
Palmer, T. M. et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 347, f4262 (2013).PubMedPubMedCentral
140.
Hughes, K., Flynn, T., de Zoysa, J., Dalbeth, N. & Merriman, T. R. Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function. Kidney Int. 85, 344–351 (2014).PubMed
141.
Lyngdoh, T. et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One 7, e39321 (2012).PubMedPubMedCentral
142.
Merola, J. F., Wu, S., Han, J., Choi, H. K. & Qureshi, A. A. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann. Rheum. Dis. http://​dx.​doi.​org/​10.​1136/​annrheumdis-2014-205212.
143.
Reynolds, M. D. Gout and hyperuricemia associated with sickle-cell anemia. Semin. Arthritis Rheum. 12, 404–413 (1983).PubMed
144.
McAdams-DeMarco, M. A., Maynard, J. W., Coresh, J. & Baer, A. N. Anemia and the onset of gout in a population-based cohort of adults: Atherosclerosis Risk in Communities study. Arthritis Res. Ther. 14, R193 (2012).PubMedPubMedCentral
145.
Khokhar, N. Gouty arthritis in chronic obstructive pulmonary disease. Arch. Intern. Med. 142, 838 (1982).PubMed
146.
Kuzell, W. C. et al. Some observations on 520 gouty patients. J. Chronic Dis. 2, 645–669 (1955).PubMed
147.
Durward, W. F. Letter: Gout and hypothyroidism in males. Arthritis Rheum. 19, 123 (1976).PubMed
148.
Erickson, A. R., Enzenauer, R. J., Nordstrom, D. M. & Merenich, J. A. The prevalence of hypothyroidism in gout. Am. J. Med. 97, 231–234 (1994).PubMed
149.
See, L. C. et al. Hyperthyroid and hypothyroid status was strongly associated with gout and weakly associated with hyperuricaemia. PLoS One 9, e114579 (2014).PubMedPubMedCentral
150.
Mariani, L. H. & Berns, J. S. The renal manifestations of thyroid disease. J. Am. Soc. Nephrol. 23, 22–26 (2012).PubMed
151.
Bruderer, S., Bodmer, M., Jick, S. S. & Meier, C. R. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol. 66, 185–196 (2014).PubMed
152.
Choi, H. K., Soriano, L. C., Zhang, Y. & Rodriguez, L. A. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 344, d8190 (2012).PubMedPubMedCentral
153.
McAdams-DeMarco, M. A. et al. A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study. Ann. Rheum. Dis. 72, 701–706 (2013).PubMed
154.
Lin, H. Y. et al. Cyclosporine-induced hyperuricemia and gout. N. Engl. J. Med. 321, 287–292 (1989).PubMed
155.
Stamp, L., Searle, M., O'Donnell, J. & Chapman, P. Gout in solid organ transplantation: a challenging clinical problem. Drugs 65, 2593–2611 (2005).PubMed
156.
So, A. & Thorens, B. Uric acid transport and disease. J. Clin. Invest. 120, 1791–1799 (2010).PubMedPubMedCentral
157.
Zhang, Y. et al. Low-dose aspirin use and recurrent gout attacks. Ann. Rheum. Dis. 73, 385–390 (2014).PubMed
158.
Fazio, S. et al. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes Obes. Metab. 12, 983–993 (2010).PubMed
159.
Amodio, M. I., Bengualid, V. & Lowy, F. D. Development of acute gout secondary to pyrazinamide in a patient without a prior history of gout. DICP 24, 1115–1116 (1990).PubMed
160.
Rao, T. P. & Schmitt, J. K. Gout secondary to pyrazinamide and ethambutol. Va Med. Q. 123, 271 (1996).PubMed
161.
Creighton, S., Miller, R., Edwards, S., Copas, A. & French, P. Is ritonavir boosting associated with gout? Int. J. STD AIDS 16, 362–364 (2005).PubMed
162.
Ball, G. V. Two epidemics of gout. Bull. Hist. Med. 45, 401–408 (1971).PubMed
163.
Lin, J. L., Tan, D. T., Ho, H. H. & Yu, C. C. Environmental lead exposure and urate excretion in the general population. Am. J. Med. 113, 563–568 (2002).PubMed
164.
Krishnan, E., Lingala, B. & Bhalla, V. Low-level lead exposure and the prevalence of gout: an observational study. Ann. Intern. Med. 157, 233–241 (2012).PubMed
165.
Shadick, N. A. et al. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J. Rheumatol. 27, 1708–1712 (2000).PubMed
166.
Lin, J. L., Lin-Tan, D. T., Hsu, K. H. & Yu, C. C. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N. Engl. J. Med. 348, 277–286 (2003).PubMed
167.
Martillo, M. A., Nazzal, L. & Crittenden, D. B. The crystallization of monosodium urate. Curr. Rheumatol. Rep. 16, 400 (2014).PubMedPubMedCentral
168.
Burt, H. M. & Dutt, Y. C. Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann. Rheum. Dis. 45, 858–864 (1986).PubMedPubMedCentral
169.
Wilcox, W. R. & Khalaf, A. A. Nucleation of monosodium urate crystals. Ann. Rheum. Dis. 34, 332–339 (1975).PubMedPubMedCentral
170.
Tak, H. K., Wilcox, W. R. & Cooper, S. M. The effect of lead upon urate nucleation. Arthritis Rheum. 24, 1291–1295 (1981).PubMed
171.
Perricone, E. & Brandt, K. D. Enhancement of urate solubility by connective tissue. I. Effect of proteoglycan aggregates and buffer cation. Arthritis Rheum. 21, 453–460 (1978).PubMed
172.
Pascual, E. & Ordonez, S. Orderly arrayed deposit of urate crystals in gout suggest epitaxial formation. Ann. Rheum. Dis. 57, 255 (1998).PubMedPubMedCentral
173.
Simkin, P. A. The pathogenesis of podagra. Ann. Intern. Med. 86, 230–233 (1977).PubMed
174.
Zhang, Y. et al. Purine-rich foods intake and recurrent gout attacks. Ann. Rheum. Dis. 71, 1448–1453 (2012).PubMed
175.
Neogi, T. et al. Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study. Am. J. Med. 127, 311–318 (2014).PubMedPubMedCentral
176.
Choi, H. K. & Curhan, G. Coffee consumption and risk of incident gout in women: the Nurses' Health Study. Am. J. Clin. Nutr. 92, 922–927 (2010).PubMedPubMedCentral
177.
Roubenoff, R. et al. Incidence and risk factors for gout in white men. JAMA 266, 3004–3007 (1991).PubMed
178.
Hochberg, M. C. et al. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 38, 628–632 (1995).PubMed
179.
Krishnan, E. Gout in African Americans. Am. J. Med. 127, 858–864 (2014).PubMed
180.
Currie, W. J. Prevalence and incidence of the diagnosis of gout in Great Britain. Ann. Rheum. Dis. 38, 101–106 (1979).PubMedPubMedCentral
181.
Isomäki, H., Raunio, J., von Essen, R. & Hämeenkorpi, R. Incidence of inflammatory rheumatic diseases in Finland. Scand. J. Rheumatol 7, 188–192 (1978).PubMed
182.
Williams, P. T. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am. J. Clin. Nutr. 87, 1480–1487 (2008).PubMed
183.
DeMarco, M. M., Maynard, J. W., Baer, A. N. & Coresh, J. Alcohol intake is associated with incident gout among black and white, men and women in the Atherosclerosis Risk in Communities Study [abstract]. Arthritis Rheum. 63 (Suppl. 10), 887 (2011).
184.
Zhang, Y. et al. Alcohol consumption as a trigger of recurrent gout attacks. Am. J. Med. 119, 800.e11–800.e16 (2006).
185.
Bhole, V., de Vera, M., Rahman, M. M., Krishnan, E. & Choi, H. Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis. Rheum. 62, 1069–1076 (2010).PubMed
186.
Lyu, L. C. et al. A case-control study of the association of diet and obesity with gout in Taiwan. Am. J. Clin. Nutr. 78, 690–701 (2003).PubMed
187.
Zhang, W. et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1301–1311 (2006).PubMedPubMedCentral
188.
Kellgren, J. H. et al. (Eds) The epidemiology of chronic rheumatism Vol. 1 (Blackwell, 1963).
189.
Wallace, S. L. et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 20, 895–900 (1977).PubMed
190.
Malik, A., Schumacher, H. R., Dinnella, J. E. & Clayburne, G. M. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin. Rheumatol. 15, 22–24 (2009).PubMed
191.
Taylor, W. J. et al. Performance of classification criteria for gout in early and established disease. Ann. Rheum. Dis. (2014).
192.
Neogi, T. et al. The Proposed New Preliminary Gout Classification Criteria. Annual Congress of American College of Rheumatology (2014).
193.
McAdams, M. A. et al. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J. Rheumatol. 38, 135–141 (2011).PubMed
194.
Harrold, L. R. et al. Validity of gout diagnoses in administrative data. Arthritis Rheum. 57, 103–108 (2007).PubMed
195.
Singh, J. A., Hodges, J. S., Toscano, J. P. & Asch, S. M. Quality of care for gout in the US needs improvement. Arthritis Rheum. 57, 822–829 (2007).PubMedPubMedCentral
196.
Meier, C. R. & Jick, H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br. J. Clin Pharmacol 44, 175–178 (1997).PubMedPubMedCentral
197.
Taylor, W. J. et al. Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping. Arthritis Rheum. 61, 535–543 (2009).PubMed